Sarepta Therapeutics/$SRPT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Sarepta Therapeutics

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Ticker

$SRPT
Sector
Primary listing

Employees

1,372

SRPT Metrics

BasicAdvanced
$2.2B
-
-$0.60
0.49
-

What the Analysts think about SRPT

Analyst ratings (Buy, Hold, Sell) for Sarepta Therapeutics stock.

Bulls say / Bears say

FDA advisers voted 8-6 in May 2025 to support accelerated approval of Sarepta’s SRP-9001 gene therapy for Duchenne muscular dystrophy, enhancing likelihood of U.S. market entry and revenue growth. (Reuters)
Positive phase 1/2 SRP-9003 trial data showed 73% mean signal intensity and an 89% mean reduction in creatine kinase in high-dose cohorts for limb-girdle muscular dystrophy type 2E, underscoring pipeline diversification beyond DMD. (Reuters)
Collaboration with Codiak Biosciences grants Sarepta access to exosome-based platforms and up to $72.5 million in upfront and near-term payments, bolstering non-dilutive funding and pipeline expansion. (Reuters)
The European Medicines Agency declined to back Sarepta’s Elevidys gene therapy for DMD and the U.S. FDA halted all shipments, causing shares to drop nearly 13% and down 88.8% year-to-date, signaling regulatory and commercialization setbacks. (Reuters)
Elevidys was linked to the first reported fatal liver injury when a teenage boy died of acute liver failure post-treatment, intensifying safety concerns and regulatory scrutiny. (Bloomberg)
Following the death of a 51-year-old trial participant, Sarepta announced study halts and layoffs; the stock plunged 25% amid criticism over delayed disclosure and broader financial strain. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.

SRPT Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

SRPT Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SRPT

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs